TY - JOUR
T1 - Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
AU - Chigrinova, Ekaterina
AU - Rinaldi, Andrea
AU - Kwee, Ivo
AU - Rossi, Davide
AU - Rancoita, Paola M.V.
AU - Strefford, Jonathan C.
AU - Oscier, David
AU - Stamatopoulos, Kostas
AU - Papadaki, Theodora
AU - Berger, Francoise
AU - Young, Ken H.
AU - Murray, Fiona
AU - Rosenquist, Richard
AU - Greiner, Timothy C.
AU - Chan, Wing C.
AU - Orlandi, Ester M.
AU - Lucioni, Marco
AU - Marasca, Roberto
AU - Inghirami, Giorgio
AU - Ladetto, Marco
AU - Forconi, Francesco
AU - Cogliatti, Sergio
AU - Votavova, Hana
AU - Swerdlow, Steven H.
AU - Stilgenbauer, Stephan
AU - Piris, Miguel A.
AU - Matolcsy, Andras
AU - Spagnolo, Dominic
AU - Nikitin, Eugene
AU - Zamò, Alberto
AU - Gattei, Valter
AU - Bhagat, Govind
AU - Ott, German
AU - Zucca, Emanuele
AU - Gaidano, Gianluca
AU - Bertoni, Francesco
N1 - Funding Information:
This work was supported by Oncosuisse OCS 02296-08-2008 (to F. Bertoni), the Helmut Horten Foundation (to F. Bertoni), the San Salvatore Foundation (to F. Bertoni), the Nelia et Amadeo Barletta Foundation (to F. Bertoni), Computational Life Sciences/Ticino in Rete (to F. Bertoni), and DFG-SFB1074, subproject B2 (to S.S.). E.C. was a recipient of an European Society for Medical Oncology (ESMO) Fellowship Grant.
Publisher Copyright:
© 2013 by The American Society of Hematology.
PY - 2013
Y1 - 2013
N2 - Richter syndrome (RS) occurs in up to 15% of patients with chronic lymphocytic leukemia (CLL). Although RS, usually represented by the histologic transformation to a diffuse large B-cell lymphoma (DLBCL), is associated with a very poor outcome, especially when clonally related to the preexisting CLL, the mechanisms leading to RS have not been clarified. To better understand the pathogenesis of RS, we analyzed a series of cases including 59 RS, 28 CLL phase of RS, 315 CLL, and 127 de novo DLBCL. RS demonstrated a genomic complexity intermediate between CLL and DLBCL. Cell-cycle deregulation via inactivation of TP53 and of CDKN2A was a main mechanism in the histologic transformation from CLL phase, being present in approximately one half of the cases, and affected the outcome of the RS patients. A second major subgroup was characterized by the presence of trisomy 12 and comprised one third of the cases. Although RS shared some of the lesions seen in de novo DLBCL, its genomic profile was clearly separate. The CLL phase preceding RS had not a generalized increase in genomic complexity compared with untransformed CLL, but it presented clear differences in the frequency of specific genetic lesions.
AB - Richter syndrome (RS) occurs in up to 15% of patients with chronic lymphocytic leukemia (CLL). Although RS, usually represented by the histologic transformation to a diffuse large B-cell lymphoma (DLBCL), is associated with a very poor outcome, especially when clonally related to the preexisting CLL, the mechanisms leading to RS have not been clarified. To better understand the pathogenesis of RS, we analyzed a series of cases including 59 RS, 28 CLL phase of RS, 315 CLL, and 127 de novo DLBCL. RS demonstrated a genomic complexity intermediate between CLL and DLBCL. Cell-cycle deregulation via inactivation of TP53 and of CDKN2A was a main mechanism in the histologic transformation from CLL phase, being present in approximately one half of the cases, and affected the outcome of the RS patients. A second major subgroup was characterized by the presence of trisomy 12 and comprised one third of the cases. Although RS shared some of the lesions seen in de novo DLBCL, its genomic profile was clearly separate. The CLL phase preceding RS had not a generalized increase in genomic complexity compared with untransformed CLL, but it presented clear differences in the frequency of specific genetic lesions.
UR - http://www.scopus.com/inward/record.url?scp=84891038503&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891038503&partnerID=8YFLogxK
U2 - 10.1182/blood-2013-03-489518
DO - 10.1182/blood-2013-03-489518
M3 - Article
C2 - 24004666
AN - SCOPUS:84891038503
SN - 0006-4971
VL - 122
SP - 2673
EP - 2682
JO - Blood
JF - Blood
IS - 15
ER -